<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465579</url>
  </required_header>
  <id_info>
    <org_study_id>IRST185.05</org_study_id>
    <nct_id>NCT03465579</nct_id>
  </id_info>
  <brief_title>Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.</brief_title>
  <acronym>BIOPSTAGE</acronym>
  <official_title>Multi-cohort Investigational Study to Evaluate the Impact of Pelvic Mp-3TMRI and Whole-body 68Ga-PSMA PET/CT for Diagnosis of Clinically-significant Prostate Cancer and Pre-surgical Staging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOPSTAGE is a prospective, non-randomized, diagnostic, multi-cohort investigational study to&#xD;
      evaluate the impact of pelvic Multi-parametric 3-Tesla magnetic resonance imaging (mp-3TMRI)&#xD;
      and whole-body 68Ga-PSMA PET/CT for diagnosis of clinically-significant prostate cancer and&#xD;
      pre-surgical staging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to characterize the diagnostic accuracy of both multi-parametric&#xD;
      pelvic Magnetic Resonance Imaging (MRI) (T2-weighted, Diffusion Weighted Imaging (DWI),&#xD;
      Dynamic Contrast Enhancement (DCE) and 68Ga-chelated Prostate Specific Membrane Antigen&#xD;
      ligand (68Ga-PSMA) Positron Emission Tomography/Computed Tomography (PET /CT) in three&#xD;
      cohorts of patients:&#xD;
&#xD;
        -  COHORT 1 Guiding prostate biopsies in men with clinical suspicion and/or unconfirmed&#xD;
           clinically-significant prostate cancer (CS-PCa) on initial prostate biopsy;&#xD;
&#xD;
        -  COHORT 2 Targeting repeat prostate biopsy in patients on Active Surveillance (PRIAS&#xD;
           Study), scheduled for PRIAS repeat biopsy;&#xD;
&#xD;
        -  COHORT 3&#xD;
&#xD;
      Providing pelvic / whole-body pre-surgical staging in:&#xD;
&#xD;
        -  3a: men with high-risk PCa (HR-PCa);&#xD;
&#xD;
        -  3b: men candidates for nerve sparing surgery (NSS);&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity of both 68Ga-PSMA PET/CT and mp-3TMRI imaging</measure>
    <time_frame>up to 36 months</time_frame>
    <description>sensitivity of both 68Ga-PSMA PET/CT and mp-3TMRI imaging will be calculated as the ratio between the number of positive cases at 68Ga-PSMA PET/CT or mp-3TMRI and number of patients who underwent to these exams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>specificity of both 68Ga-PSMA PET/CT and mp-3TMRI imaging</measure>
    <time_frame>up to 36 months</time_frame>
    <description>specificity will be calculated considering negative cases at 68Ga-PSMA PET/CT or mp-3TMRI and number of patients who underwent to these exams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive predictive value of both 68Ga-PSMA PET/CT and mp-3TMRI imaging</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Positive predictive value will be calculated considering the ratio between positive patient at 68Ga-PSMA PET/CT/mp-3TMRI confirmed as positive throughout biopsy and overall positive patient at 68Ga-PSMA PET/CT/mp-3TMRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>negative predictive value of both 68Ga-PSMA PET/CT and mp-3TMRI imaging</measure>
    <time_frame>up to 36 months</time_frame>
    <description>negative predictive value will be calculated considering the ratio between negative patient at 68Ga-PSMA PET/CT/mp-3TMRI confirmed as negative throughout biopsy and overall negative patient at 68Ga-PSMA PET/CT/mp-3TMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 30 days following study procedures</time_frame>
    <description>The number and percentage of treated patients undergoing grade 1 to 4 adverse events will be tabulated for each cohort and diagnostic procedure, using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 should be used to assess and grade AE severity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>68Ga-PSMA PET/CT Guided Prostate Biopsy</condition>
  <condition>Mp-3TMRI Guided Prostate Biopsy</condition>
  <condition>Prostate Cancer</condition>
  <condition>TNM Staging</condition>
  <condition>Diagnosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Men with high-risk PCa (HR-PCa) prior to radical surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pelvic MRI</intervention_name>
    <description>multi-parametric pelvic MRI</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_label>Cohort 3b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-PSMA PET/CT</intervention_name>
    <description>68Ga-PSMA PET/CT</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_label>Cohort 3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1 - Biopsy guidance in clinically-suspected PCa&#xD;
&#xD;
        1. Men aged 45 to 75 years old with clinically-suspected PCa candidated for either initial&#xD;
        or repeat TRUS-guided prostate biopsy, meeting any of the following criteria:&#xD;
&#xD;
        a) Abnormal PSA metrics, defined as follows:&#xD;
&#xD;
        A rising and/or persistently elevated serum PSA (i.e PSA &gt; 2.5ng/ml for men in the age&#xD;
        group comprising 60 to 75 years old; PSA &gt; 3.0ng/ml for men in the age group comprising 45&#xD;
        to 60 years old) and at least one of the following PSA-based metrics:&#xD;
&#xD;
        i. Percent free PSA (%fPSA) &lt; 25% with PSA range 4-10ng/ml (NCCN); ii. PSA velocity&#xD;
        (PSAvel) &gt;0.35 ng/mL/y; iii. PSA density (PSAden) &gt; 0.25ng/mL/cc iv. PSA &gt; 10ng/ml, 50%&#xD;
        risk of PCa (EAU) b) Suspicious digital rectal examination (DRE), 5-30% risk of PCa; c)&#xD;
        Prostate Cancer Gene 3 (PCA3) &gt; 35; d) Suspicious findings on first-round biopsy: i. A few&#xD;
        Atypical Glands immediately adjacent to HG-PIN, 50% risk of PCa; ii. Atypical Small Acinar&#xD;
        Proliferation, 40% of PCa; iii. Multifocal High-Grade Prostatic intraepithelial neoplasia&#xD;
        (HG-PIN), 30% ; iv. Intraductal carcinoma as solitary finding, 90% of PCa;&#xD;
&#xD;
        Cohort 2 - Biopsy guidance on Active Surveillance&#xD;
&#xD;
        Men consenting to enter the PRIAS MRI side-study as per currently inclusion criteria in&#xD;
        Version Number 1.0 dated August 20, 2013. These are:&#xD;
&#xD;
          1. Histologically-proven adenocarcinoma of the prostate;&#xD;
&#xD;
          2. Age â‰¥ 18&#xD;
&#xD;
          3. Men should be fit for curative treatment;&#xD;
&#xD;
          4. Clinical stage T1c or T2;&#xD;
&#xD;
          5. Gleason score 3+3=6;&#xD;
&#xD;
          6. One or two biopsy cores invaded with prostate cancer:&#xD;
&#xD;
               1. If an MRI, including targeted biopsies on positive lesions, is done at inclusion,&#xD;
                  there is no limit in the number of positive cores (that is, more than two, and no&#xD;
                  limit in the % of cancer present in the cores);&#xD;
&#xD;
               2. If saturation biopsies (either trans-perineal or trans-rectal) are done 15% of&#xD;
                  the cores can be positive with a maximum of 4 (i.e. 26 cores 4 cores can be&#xD;
                  positive) (all other inclusion criteria still apply);&#xD;
&#xD;
          7. PSA density (PSA D) less than 0.2;&#xD;
&#xD;
          8. PSA-level at diagnosis â‰¤ 10 ng/mL;&#xD;
&#xD;
        Cohort 3a - Pre-surgical TNM staging in high-risk prostate cancer&#xD;
&#xD;
          1. Male, aged 18 years or older;&#xD;
&#xD;
          2. Cyto / histological confirmation of PCa (i.e. TRUS-guided biopsies; TURP);&#xD;
&#xD;
          3. Any of the PCa high risk features for Organ-Confined Disease (OCD):&#xD;
&#xD;
               -  Clinical T stage â‰¥ T2c;&#xD;
&#xD;
               -  Gleason Score â‰¥ 8;&#xD;
&#xD;
               -  Serum PSA &gt; 20 ng/mL;&#xD;
&#xD;
          4. Any of the PCa high-risk features for Locally-Advanced Disease (LAD):&#xD;
&#xD;
               -  Clinical T stage â‰¥ T3b-T4 OR any T and clinical N1 disease;&#xD;
&#xD;
               -  Gleason Score â‰¥ 8;&#xD;
&#xD;
               -  Serum PSA &gt; 20 ng/mL;&#xD;
&#xD;
          5. Routine clinical staging (CTscan Â± Bone scan) performed within 12 weeks enrolment&#xD;
             returning negative or equivocal results for distant metastatic disease;&#xD;
&#xD;
        Cohort 3b - pelvic TNM staging of prostate cancer prior to nerve-sparing radical&#xD;
        prostatectomy&#xD;
&#xD;
          1. Male, aged 18 years or older;&#xD;
&#xD;
          2. Cyto / histological confirmation of PCa (i.e. TRUS-guided biopsies; TURP);&#xD;
&#xD;
          3. All of the following PCa-related features must be met for nerve-sparing (either mono-&#xD;
             or bi-lateral):&#xD;
&#xD;
               -  Clinical T stage â‰¤ T2b;&#xD;
&#xD;
               -  Gleason Score â‰¤ 7 (3+4) and maximum one biopsy with Gleason &gt; 6 at the&#xD;
                  ipsilateral side;&#xD;
&#xD;
               -  Serum PSA &lt; 10 ng/mL;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The participant may not enter the study if ANY of the following apply:&#xD;
&#xD;
          1. Hormone androgen deprivation therapy of any type within 6 months prior to enrollment.&#xD;
&#xD;
          2. Prior pelvic radiotherapy;&#xD;
&#xD;
          3. Sickle cell disease;&#xD;
&#xD;
          4. Insufficient renal function (eGFR &lt; 30 mL/min/1.73 m2);&#xD;
&#xD;
          5. Hip prosthesis, vascular grafting or other conditions affecting imaging;&#xD;
&#xD;
          6. Contraindication to MRI, including but not restricted to: pacemaker or other&#xD;
             electronic im-plants, known metal in the orbit, MR incompatible surgical or cerebral&#xD;
             aneurysm clips, shrapnel, tattoos, non-removable body piercings (relative&#xD;
             contraindications);&#xD;
&#xD;
          7. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             com-position to 68Ga-PSMA or Gadolinium-based contrast agents used in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federica Matteucci</last_name>
    <role>Study Chair</role>
    <affiliation>IRST IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana Nanni</last_name>
    <phone>+390543739266</phone>
    <email>oriana.nanni@irst.emr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federica Matteucci, MD</last_name>
    <phone>+390543739100</phone>
    <email>federica.matteucci@irst.emr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AUSL della Romagna</name>
      <address>
        <city>ForlÃ¬</city>
        <state>FC</state>
        <zip>47121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Gunelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Matteucci, MD</last_name>
      <phone>+390543739100</phone>
      <email>federica.matteucci@irst.emr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnosis Prostate Cancer</keyword>
  <keyword>TNM staging</keyword>
  <keyword>68Ga-PSMA PET/CT guided prostate biopsy</keyword>
  <keyword>mp-3TMRI guided prostate biopsy</keyword>
  <keyword>pre-surgical staging</keyword>
  <keyword>clinically-suspected prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

